Literature DB >> 23981988

[DNA methylation status of miR-126 and its host gene EGFL7 in CD4+ T cells from patients with systemic lupus erythematosus].

Yunsheng Liang1, Sha Zhao, Gongping Liang, Ming Zhao, Qianjin Lu.   

Abstract

OBJECTIVE: To explore the mechanisms by which DNA methylation regulates miR-126 and its host gene EGFL7 in CD4+ T cells from patients with systemic lupus erythematosus (SLE).
METHODS: We analyzed the expression and the DNA methylation status within promoter region of EGFL7 and miR-126 by real-time qPCR and bisulfite genomic sequencing analysis.
RESULTS: miR-126 and EGFL7 mRNA expression was upregulated in CD4+ T cells from SLE compared with that from healthy controls (P<0.01). EGFL7 mRNA level was positively correlated with miR-126 expression in CD4+ T cells from SLE (r=0.538, P=0.015). The average methylation level of EGFL7 promoter in CD4+ T cells from SLE was lower than that from healthy controls (P<0.05).
CONCLUSION: The upregulation of miR-126 and its host gene EGFL7 expression in CD4+ T cells from SLE is associated with the hypomethylation of the EGFL7 promoter.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23981988     DOI: 10.3969/j.issn.1672-7347.2013.08.006

Source DB:  PubMed          Journal:  Zhong Nan Da Xue Xue Bao Yi Xue Ban        ISSN: 1672-7347


  3 in total

1.  MiR-126 correlates with increased disease severity and promotes keratinocytes proliferation and inflammation while suppresses cells' apoptosis in psoriasis.

Authors:  Shike Feng; Lin Wang; Wang Liu; Yan Zhong; Shijun Xu
Journal:  J Clin Lab Anal       Date:  2018-06-26       Impact factor: 2.352

Review 2.  DNA methylation alterations in the pathogenesis of lupus.

Authors:  S H Chen; Q L Lv; L Hu; M J Peng; G H Wang; B Sun
Journal:  Clin Exp Immunol       Date:  2016-11-01       Impact factor: 4.330

Review 3.  Epigenetic Aspects of Systemic Lupus Erythematosus.

Authors:  Manfred Relle; Bernd Foehr; Andreas Schwarting
Journal:  Rheumatol Ther       Date:  2015-06-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.